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Background: The present study set out to detect and identify amoxicillin–clavulanic acid (AMC)-resistant Enterobacteriaceae in fecal samples of
two patients with cystic ﬁbrosis (CF) and their respective siblings.
Methods: Fecal Enterobacteriaceae were enumerated onto EMB agar containing amoxicillin (AMX). A total of 173 CF isolates and 41 sibling
isolates were grouped into seven Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) clusters and
identiﬁed through 16S rRNA and rpoB sequence analysis.
Results: The fecal microbiota of patients with CF revealed a higher prevalence of AMX resistant Enterobacteriaceae compared to that of their
healthy siblings. Whereas all selected isolates of healthy siblings were assigned to Escherichia coli, isolates of patients with CF belonged to
Klebsiella oxytoca (58.4%), E. coli (28.3%), Klebsiella variicola (7.5%) or Citrobacter sp. (5.8%). All tested CF isolates showed a high resistance
rate to AMX, and a lower level of resistance to the combination with clavulanic acid. In contrast, all tested sibling isolates were susceptible for both
AMX and AMC.
Conclusion: The higher abundance of AMX resistance in the investigated patients with CF suggests that frequent AMC administration may be one
of the major contributing factors in the proliferation of Enterobacteriaceae and the development of resistant strains in the gastrointestinal tract.
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fibrosis (CF) are currently managed with frequent treatment
with high doses of multiple antimicrobial agents. Whereas the
effect of recurrent antibiotic therapies on CF-lung microbiota has
been extensively studied [1,2], their influence on the digestive
microbiota in this patient population is poorly documented [3–5].
In studies of populations without chronic clinical diseases,
however, it has been shown that antibiotics may trigger a
substantial reduction of metabolically important bacterial groups
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http://dx.doi.org/10.1016/j.jcf.2013.06.006proliferate upon antimicrobial administration [8,9]. Furthermore,
the selective pressure of prolonged antibiotic treatment in patients
with CF may promote exchange of resistance genes triggering
proliferation of antimicrobial resistant strains [10]. Antibiotic
therapy may also decrease colonization resistance eliciting
overgrowth with already-present yeasts and/or opportunistic
pathogenic bacteria such as Clostridium difficile [11]. Depending
on the severity of the dysbiosis, these microorganisms may enter
the bloodstream and cause systemic infection. Evidence that
even short periods of antibiotic treatment can cause long-term
persistence of resistant bacteria in the gut exists [12].
Amoxicillin (AMX), a broad-spectrum β-lactam penicillin,
is recommended by the European guidelines as the first-choice
antibiotic for treating mild respiratory and other common
infections in non-hospitalized patients [13]. Despite theseby Elsevier B.V. All rights reserved.
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the use of AMX in combination with the β-lactamase inhibitor
clavulanic acid for treating lower respiratory tract infections.
Amoxicillin–clavulanic acid (AMC) serves to treat more severe
lower respiratory tract infections such as pulmonary exacerba-
tions with Staphylococcus aureus and/orHaemophilus influenzae
in young patients with CF [14]. Frequent use of these antibiotics
increases the concern for emerging development and spread of
antibiotic resistance genes. Within the Enterobacteriaceae, a
bacterial family which is typically associated with abdominal
infections, resistant isolates have been frequently isolated from
intestinal microbiota following AMX [15,16] and AMC [17]
administration, and may consequently pose a significant thera-
peutic challenge. From a clinical point of view, it is thus relevant to
gain more insight into the impact of frequent antibiotic treatment
courses on the development of antimicrobial resistant strains in the
gut of patients with CF. In the present study, the prevalence and
identity of AMC resistant fecal Enterobacteriaceae were com-
pared between two patients with CF and their respective healthy
siblings.
Stool samples were collected from 2 patients with CF and their
corresponding healthy sibling (Table 1). A detailed description of
the materials and methods is available as Supplementary content.Table 1
Overview of clinical characteristics of volunteers, isolates, MALDI-TOF MS results
Volunteer Date of
birth
Sampling
date
Sample
code
Antibiotic history a
Antibiotic agent,
route and doses
Administration
period
Patient 1 12/03/2005 17/02/2008 P1-s1 Augmentin PO
3 × 4 ml
15/10/2007–01
05/2008
4/08/2008 P1-s2 Augmentin PO
3 × 225 mg
10/07/2008–01
08/2008
2/05/2009 P1-s3 Augmentin PO
3 × 5 ml
3/02/2009–10/
02/2009
Duracef PO
3 × 5 ml
10/02/2009–23
04/2009
Tobramycin INH
2 × 1 amp
13/02/2009–12
03/2009
Ciproxin PO
3 × 150 mg
23/04/2009–23
07/2009
Colistine b INH
2 × 2 million units
23/04/2009–23
07/2009
Sibling 1 20/09/2001 17/02/2008 S1-s1 No N 1.5 years N/A
4/08/2008 S1-s2 No N/A
2/05/2009 S1-s3 No N/A
Patient 2 2/07/1998 1/12/2007 P2-s1 Augmentin PO
4 × 250 mg
27/11/2007–4/
12/2007
Sibling 2 7/05/1992 2/12/2007 S2-s1 No N 3 years N/A
a PO: per oral; INH: inhaled, N/A: not applicable.
b Concentration of AMX (μg/ml) in EMB agar plates from which the isolates we
c AMX: amoxicillin, AMC: amoxicillin–clavulanic acid.
d Only yeasts could be recovered for this sample.The prevalence of AMX resistant Enterobacteriaceae was
assessed by determining the number of colony forming units
per gram fecal sample (CFU/g) from eosin methylene blue
(EMB) agar plates containing 0, 8 and 128 ppm AMX. Samples
of the two patients with CF consistently yielded higher counts on
EMB agar without AMX (6.77 ± 1.06 mean log10 CFU/g)
compared to healthy siblings (5.80 ± 0.81 mean log10 CFU/g).
On plates containing 8 ppm AMX, no decrease in CFU was
observed for fecal samples of patients with CF (6.91 ± 0.03mean
log10 CFU/g), while for fecal samples of healthy siblings the
counts drastically declined (2.06 ± 0.84 mean log10 CFU/g). On
plates containing 128 ppm AMX, the EMB agar counts for
samples of patients with CF (6.91 ± 0.03 mean log10 CFU/g)
were still within the same range as counts on plates containing 0
or 8 ppm AMX. For samples of healthy siblings, counts on plates
containing 128 ppmAMXdecreased to an average of 1.58 ± 3.36
mean log10 CFU/g.
Following enumeration, a total of 173 patient isolates and 41
sibling isolates were collected. No isolates were obtained from
sample P1s3. Despite the inclusion of an antifungal agent in the
medium, only yeast colonies were recovered from this sample.
Matrix-Assisted Laser Desorption Ionization-Time Of Flight
Mass Spectrometry (MALDI-TOF MS) was used to dereplicate, sequencing results and MICs.
No. of
isolates
MALDI-TOF
MS clusters
Final
identification
Source
(μg/ml
AMX) b
MIC range
AMXc AMCc
/ 80 IV Klebsiella oxytoca 4 – 2/1
128 256 –
256 N256 2/1
18 VII E. coli 4 N256 32/16
128 N256 32/16
/ 21 IV Klebsiella oxytoca, 128 N256 16/8–32/16
13 V Klebsiella variicola 128 N256 8/4–16/8
10 VI Citrobacter spp. 16 N256 32/16
128 N256 32/16
13 VII E. coli 16 N256 8/4
128 N256 4/2–32/16
0 d – – – – –
/
/
/
/
20 III E. coli 1 4 2/1
4 III E. coli 8 8 4/2
15 I E. coli – – –
3 I E. coli 256 N256 8/4
15 II 256 N256 8/4
128 N256 –
2 I E. coli 1 8 2/1
re picked.
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Fig. 1. Distribution of amoxicillin–clavulanic acidMIC values (μg/ml) for isolates
obtained from 3 patients (n = 20) with CF and 3 healthy siblings (n = 3). Brackets
indicate interpretive breakpoints following CLSI criteria: susceptible ] intermedi-
ate resistance [ resistant.
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clusters were delineated at 75% Pearson similarity following
visual evaluation of the position and intensity of the peaks of
the mass spectra (Fig. S1). Next, representatives of each cluster
were selected for further taxonomic characterization.
Partial 16S rRNA gene sequence analysis confirmed that all
selected isolates belonged to the Enterobacteriaceae (data not
shown). Subsequently, partial rpoB sequence analysis was used
to obtain identification at the species level. Based on the
results of the BLAST analysis (N99% rpoB sequence similarity
with the type strain), the topology of the rpoB sequence-based
ML tree (Fig. S2) and API-20E tests (bioMérieux) (data not
shown), isolates of MALDI-TOF MS clusters I, II, III and VII
were identified as Escherichia coli and members of cluster IV
were identified as Klebsiella oxytoca. Strains that were
grouped in cluster V were assigned by rpoB sequencing to the
closely related species group Klebsiella variicola/pneumoniae/
singaporensis (N98% sequence similarity towards the type
strains), but are most closely positioned to K. variicola on the
basis of the topology of the rpoB sequence-based ML tree
(Fig. S2). Also, one representative isolate of cluster VI could
not be identified based on the BLAST analysis. Based on the
topology of the rpoB sequence-based ML tree and the API-20E
results (BioMerieux), this isolate was assigned to the genus
Citrobacter. All 41 sibling isolates were identified as E. coli,
whereas the 173 patient isolates were taxonomically more
diverse and comprised members of K. oxytoca (58.4%), E. coli
(28.3%), K. variicola (7.5%) and Citrobacter sp. (5.8%). In
healthy gut populations, E. coli is a predominant member of the
relatively small Enterobacteriaceae population. However, a
shift in species evenness is commonly observed after antimi-
crobial therapy, often characterized by lower E. coli numbers
and a higher abundance of Klebsiella sp., Enterobacter sp. and/
or Citrobacter sp. [18,19].
AMX MICs were determined for a selection (based on
isolation source and MALDI-TOF MS clustering) of 24 CF
isolates and 5 isolates obtained from sibling samples. In addition,
AMC MICs were determined for 20 CF isolates and 3 sibling
isolates. The five sibling isolates selected for AMX MIC
determination revealed MICs lower than or equal to 8 μg/ml,
and the three sibling isolates selected for AMCMIC determination
revealed MICs lower than 8/4 μg/ml, indicating that all selected
sibling isolates were susceptible for both agents according to the
CLSI breakpoints. In contrast, all tested CF-isolates (n = 24)
revealed AMX MICs N256 μg/ml, indicating a high level of
resistance towards AMX. In AMC testing, 9 isolates of patients
with CF were resistant, showing MIC values of 32/16 μg/ml
(Fig. 1). 4 CF isolates revealed AMC MICs of 16/8 μg/ml,
indicating intermediate resistance, whereas the remaining 7
isolates appeared susceptible to AMC.
The majority of all CF isolates (58.4%) were grouped in
cluster IV which was identified as K. oxytoca. Overgrowth of the
intestinal microbiota with Klebsiella species is often reported
following AMX/AMC administration [15,16]. In the current
study, all 6 selected K. oxytoca isolates were highly resistant to
AMX (MIC N 256 μg/ml). It has been previously shown that
this species can produce chromosomally encoded β-lactamases,which preferably inactivate penicillins such as AMX [20].
Moreover, mutations inβ-lactamase gene (blaOXY-1 and blaOXY-2)
promotors can lead to overproduction of β-lactamase enzymes,
causing resistance to extended-spectrum β-lactams. In the case of
P1, K. oxytoca was isolated at two different sampling points.
Whereas the two selected isolates from the first sampling point
were susceptible for AMC, all four selected isolates of the second
sampling point were intermediately to highly resistant to AMC.
This resistance may have been triggered by the antimicrobial
therapy in between the two sampling points (Table 1), although it
should be noted that this patient received the same antimicrobial
therapy prior to the first sampling as well. Adamsson and
co-workers [21] already reported that MICs can increase among
fecal Klebsiella species after antibiotic therapy with AMX. In
addition, K. variicola represented 7.5% of all CF isolates. Three
representative isolates showed a high level of AMX resistance. In
addition, two of these isolates showed an intermediate resistance
level to AMC.
Among CF isolates, E. coli accounted for 28.3% of the total.
Three selected E. coli isolates of P2 were susceptible to AMC,
while five out of the seven selected E. coli isolates of P1 were
resistant to AMC. Furthermore, these AMC resistant isolates
were observed in samples of two different sampling points of
P1, which may indicate a long-term persistence. AMX/AMC
resistance in E. coli strains is predominantly mediated by
hyper-production of plasmid-encoded TEM1 β-lactamase [22].
Isolates of cluster VI represented 5.8% of all CF isolates and
were assigned to the genus Citrobacter. All isolates of this
cluster originated from P1-s2, and its representatives revealed a
high level of resistance to AMX and AMC. This may be
explained by the intrinsic resistance of Citrobacter species to
AMX, AMC and narrow-spectrum cephalosporins through
chromosomally encoded AmpC β-lactamase enzymes [23].
In conclusion, the findings of this preliminary study indicate
a considerably higher prevalence of AMX and AMC resistant
Enterobacteriaceae in the fecal microbiota of two patients with
CF compared to their healthy siblings. This supports the
hypothesis that these patients harbor increased levels of
antibiotic resistant subpopulations in their gastrointestinal
microbiota, and that frequent AMC administration (Table 1)
may be one of the important contributing factors. An increased
783G. Duytschaever et al. / Journal of Cystic Fibrosis 12 (2013) 780–783level of resistant fecal Enterobacteriaceae may thus represent
another infectious challenge for these patients, and holds an
important reservoir for spreading resistance determinants. To
confirm this, the small range of our dataset needs to be
extended by including more patients and antimicrobial agents
and by focusing on other members of the intestinal microbiota.Acknowledgments
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